Skip to main content

Adrenal insufficiency caused by immunotherapy

Three patients receiving tislelizumab immunotherapy for NSCLC developed adrenal insufficiency, highlighting the need for awareness of pituitary–adrenal axis dysfunction as an immune-related adverse event.

Editor's Choice

Advances in therapy for non-melanoma skin cancers

Open Access Skin Cancer Review

The incidence of non-melanoma skin cancer continues to rise. Learn about the latest approved and emerging systemic therapies for locally advanced and metastatic disease.

Early menopause increases lung disease risk

Menopause before the age of 45 years increases the risk for lung morbidities and mortality in women, regardless of smoking status and whether menopause is natural or medical.

Acupuncture reduces side effects of breast cancer treatment

10-07-2024 Breast Cancer News

Acupuncture could help ease hot flashes and other endocrine symptoms in women undergoing endocrine therapy for breast cancer.

A novel side effect of ICI treatment

The first report of thoracic lymphangitis as an immune-related adverse event in a patient receiving adjuvant ICI treatment for lung cancer.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Lung Cancer Clinical Trial Summary

At a glance: The KEYNOTE lung cancer trials

A quick guide to the KEYNOTE trials investigating the anti-PD-1 agent pembrolizumab in non-small-cell and small-cell lung cancer.

Developed by: Springer Medicine
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare

Case Studies

Adrenal insufficiency caused by immunotherapy

Three patients receiving tislelizumab immunotherapy for NSCLC developed adrenal insufficiency, highlighting the need for awareness of pituitary–adrenal axis dysfunction as an immune-related adverse event.

A novel side effect of ICI treatment

The first report of thoracic lymphangitis as an immune-related adverse event in a patient receiving adjuvant ICI treatment for lung cancer.

Unprovoked VTE revealing lung cancer

Open Access Venous Thrombosis Case Study

A case emphasizing the importance of occult cancer screening in patients with unprovoked venous thromboembolism, especially those with risk factors.

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine

Current Reviews

Patient-Centered Management of Brain Tumor-Related Epilepsy

Epilepsy Review

Brain-tumor related epilepsy (BTRE) is a heterogenous syndrome associated with primary and metastatic brain tumors, accounting for 6–10% of all cases of epilepsy [ 1 ], with an average annual age-adjusted incidence rate of 24.71 per 100,000 [ 2 ].

The effect of BMI on survival outcome of breast cancer patients: a systematic review and meta-analysis

Breast Cancer REVIEW ARTICLE

Breast cancer remains the most prevalent cancer type and the primary cause of cancer-related deaths among women worldwide [ 1 ]. The latest global cancer statistics from 2022 reveal a shift where female breast cancer has surpassed lung cancer …

Mechanisms of stress-attributed breast cancer incidence and progression

Breast Cancer Review Paper

Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths in women, with psychosocial stress commonly cited by patients as one of its causes. While there is conflicting epidemiological evidence investigating …

Radiogenomics as an Integrated Approach to Glioblastoma Precision Medicine

Open Access Glioblastoma REVIEW

Isocitrate dehydrogenase wild-type glioblastoma (GBM) is the most common and aggressive primary brain tumour in adults, comprising 49% of brain malignancy [ 1 ] with a dismal median survival rate of 14 months from diagnosis [ 2 ]. The current …

NSCLC Podcast

Episode 7: A deep dive into ADAURA

The ADAURA trial has, as of this year, demonstrated an overall survival benefit with the adjuvant use of osimertinib in people with resectable NSCLC. 

We take an in-depth look at the study with Dr. Luis Paz-Ares, who outlines the study findings, discusses the clinical implications, and addresses the pertinent questions raised by the trial.

Dr. Luis Paz-Ares

CME & eLearning

eLearning (Link opens in a new window)

The evolving landscape of metastatic urothelial carcinoma brings with it many challenges, such as optimally sequencing therapies and managing adverse events. Navigate your way through these with the Ultimate mUC challenge game and expert-to-expert interviews.

Supported by:
  • Merck Healthcare KGaA, Darmstadt, Germany and Astellas
Developed by: Springer Healthcare IME

Webinar (Link opens in a new window)

1.25 AMA PRA Category 1 Credit(s)

A collaborative program highlighting the importance of molecular assessments and targeted treatment selection in people with biomarker-positive disease. Submit your questions for the experts now.

Supported by:
  • Roche and Illumina
Developed by: Springer Healthcare IME

Webcast | Videos | Cases (Link opens in a new window)

Identifying molecular biomarkers is crucial in determining the best targeted treatment options for your patients with advanced thyroid cancer.

Join our expert-led multi-format educational program that explores the continuing discovery of new genomic targets and delivers the latest research in molecular testing and the application of targeted therapies for thyroid cancer.

Start by watching our webcast and short vodcasts.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME

Further Reading

Breast density effect on the sensitivity of digital screening mammography in a UK cohort

Open Access Mammography Breast

Breast cancer is one of the most common forms of cancer and early-stage diagnosis leads to better survival [ 1 ]. Population screening programmes aim to detect cancer early and reduce mortality. The UK National Health Service Breast Screening …

Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer

Open Access Breast Cancer Original Article

Breast cancer is one of the most common malignant diseases worldwide and was the most common cancer among women in 2020 [ 1 ]. Among Japanese women, breast cancer is the most frequently diagnosed cancer, with 97,142 cases and 14,650 deaths reported …

Dose–response relationship between serum N-glycan markers and liver fibrosis in chronic hepatitis B

Open Access Hepatitis B Original Article

As of 2022, there were 257.5 million (216.6–316.4) individuals positive for HBsAg globally [ 1 ]. Decompensate cirrhosis and hepatocellular carcinoma (HCC) were the main causes of death in chronic HBV-infected individuals [ 2 – 4 ]. Over 85% of HCC …

Related topics

Advances in the management of mCRPC

Open Access Prostate Cancer Review

What are the latest advances in the ever-expanding list of treatment options for metastatic castration-resistant prostate cancer? And how can you best integrate these agents into your clinical practice?

Read more

Adrenal insufficiency caused by immunotherapy

Three patients receiving tislelizumab immunotherapy for NSCLC developed adrenal insufficiency, highlighting the need for awareness of pituitary–adrenal axis dysfunction as an immune-related adverse event.

Read more